TipRanks
Advertisement
Advertisement

SKYE Stock Latest News

Skye Bioscience CFO Resigns, CEO Assumes Financial Role
Company AnnouncementsSkye Bioscience CFO Resigns, CEO Assumes Financial Role
24d ago
8K
SKYE
Skye Bioscience Establishes New Equity Financing Arrangements
PremiumCompany Announcements
Skye Bioscience Establishes New Equity Financing Arrangements
1M ago
8K
SKYE
Upcoming Stock Splits This Week (August 24 to August 28) – Stay Invested
PremiumMarket News
Upcoming Stock Splits This Week (August 24 to August 28) – Stay Invested
1M ago
NVX
YMT
Skye Bioscience Inc trading halted, news pending
PremiumThe Fly
Skye Bioscience Inc trading halted, news pending
1M ago
SKYE
Skye Bioscience Faces Nasdaq Compliance and Delisting Risk
PremiumCompany Announcements
Skye Bioscience Faces Nasdaq Compliance and Delisting Risk
2M ago
8K
SKYE
Skye Bioscience Inc trading halted, news pending
PremiumThe FlySkye Bioscience Inc trading halted, news pending
2M ago
SKYE
Skye Bioscience to acquire Redx Pharma via scheme of arrangement
Premium
The Fly
Skye Bioscience to acquire Redx Pharma via scheme of arrangement
2M ago
SKYE
Skye Bioscience Inc trading resumes
Premium
The Fly
Skye Bioscience Inc trading resumes
2M ago
SKYE
Skye Bioscience to Merge with Redx, Form Fibrx Therapeutics
PremiumCompany Announcements
Skye Bioscience to Merge with Redx, Form Fibrx Therapeutics
2M ago
8K
SKYE
VOO vs. VTI: Are You Owning the Wrong Vanguard ETF?
PremiumMarket News
VOO vs. VTI: Are You Owning the Wrong Vanguard ETF?
2M ago
MU
SPX
Is SKYE a Buy, Before Earnings?
PremiumPre-Earnings
Is SKYE a Buy, Before Earnings?
2M ago
SKYE
Skye Bioscience Lawsuit: MFDI Seeks Dismissal of Securities Claims Against It 
PremiumClass Action
Skye Bioscience Lawsuit: MFDI Seeks Dismissal of Securities Claims Against It 
2M ago
SKYE
Skye Bioscience Lawsuit: Company and CEO Move to Dismiss Claims 
PremiumClass ActionSkye Bioscience Lawsuit: Company and CEO Move to Dismiss Claims 
2M ago
SKYE
Skye Bioscience Moves Listing to Nasdaq Capital Market
Premium
Company Announcements
Skye Bioscience Moves Listing to Nasdaq Capital Market
3M ago
8K
SKYE
Skye Bioscience Expands Authorized Shares After Shareholder Approval
Premium
Company Announcements
Skye Bioscience Expands Authorized Shares After Shareholder Approval
4M ago
8K
SKYE
Analyst Reiterates Buy on Skye Bioscience, Maintains $20 Price Target on Positive Nimacimab Safety and Efficacy Data
PremiumRatings
Analyst Reiterates Buy on Skye Bioscience, Maintains $20 Price Target on Positive Nimacimab Safety and Efficacy Data
5M ago
SKYE
Skye Bioscience Faces Nasdaq Compliance Risk Over Equity
PremiumCompany Announcements
Skye Bioscience Faces Nasdaq Compliance Risk Over Equity
5M ago
8K
SKYE
Skye Bioscience price target lowered to $6 from $13 at Piper Sandler
PremiumThe Fly
Skye Bioscience price target lowered to $6 from $13 at Piper Sandler
5M ago
SKYE
Skye Bioscience reports Q1 EPS (32c), consensus (32c)
PremiumThe Fly
Skye Bioscience reports Q1 EPS (32c), consensus (32c)
5M ago
SKYE
Skye Bioscience Faces Nasdaq Listing Compliance Deficiency Notice
PremiumCompany AnnouncementsSkye Bioscience Faces Nasdaq Listing Compliance Deficiency Notice
7M ago
8K
SKYE
SKYE Bioscience: Advancing Nimacimab Dose Expansion and Clear Phase 2b Path as Adjunct to Semaglutide Supports Buy Rating
Premium
Ratings
SKYE Bioscience: Advancing Nimacimab Dose Expansion and Clear Phase 2b Path as Adjunct to Semaglutide Supports Buy Rating
7M ago
SKYE
Skye Bioscience reports Q4 EPS (36c), consensus (31c)
Premium
The Fly
Skye Bioscience reports Q4 EPS (36c), consensus (31c)
7M ago
SKYE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >